{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T21:58:51Z","timestamp":1790459931015,"version":"4.1.0"},"reference-count":33,"publisher":"American Association for Cancer Research (AACR)","issue":"5","funder":[{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute (NCI)","doi-asserted-by":"publisher","award":["R01CA175691"],"award-info":[{"award-number":["R01CA175691"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense (DOD)","doi-asserted-by":"publisher","award":["W81XWH-14-1-0235"],"award-info":[{"award-number":["W81XWH-14-1-0235"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense (DOD)","doi-asserted-by":"publisher","award":["W81XWH-11-1-0494"],"award-info":[{"award-number":["W81XWH-11-1-0494"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jayne\/Ted Giovanis Foundation for Health and Policy"},{"name":"Palmira and James Nicolo Family Research Fund"},{"name":"#14 Mesothelioma Fund of the International Association of Heat and Frost Insulators and Allied workrs"},{"DOI":"10.13039\/100001282","name":"Ovarian Cancer Research Fund (OCRF)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001282","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001384","name":"Samuel Waxman Cancer Research Foundation (SWCRF)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001384","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute (NCI)","doi-asserted-by":"publisher","award":["R01CA175691"],"award-info":[{"award-number":["R01CA175691"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute (NCI)","doi-asserted-by":"publisher","award":["P30CA006927"],"award-info":[{"award-number":["P30CA006927"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute (NCI)","doi-asserted-by":"publisher","award":["R01CA161870"],"award-info":[{"award-number":["R01CA161870"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute (NCI)","doi-asserted-by":"publisher","award":["R01CA161870"],"award-info":[{"award-number":["R01CA161870"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute (NCI)","doi-asserted-by":"publisher","award":["R01CA163761"],"award-info":[{"award-number":["R01CA163761"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute (NCI)","doi-asserted-by":"publisher","award":["P30CA010815"],"award-info":[{"award-number":["P30CA010815"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000869","name":"Susan G. Komen for the Cure (Susan G. Komen)","doi-asserted-by":"publisher","award":["KG110708"],"award-info":[{"award-number":["KG110708"]}],"id":[{"id":"10.13039\/100000869","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense (DOD)","doi-asserted-by":"publisher","award":["W81XWH-17-1-0506"],"award-info":[{"award-number":["W81XWH-17-1-0506"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Deleterious mutations of the ubiquitin carboxy-terminal hydrolase BAP1 found in cancers are predicted to encode inactive truncated proteins, suggesting that loss of enzyme function is a primary tumorigenic mechanism. However, many tumors exhibit missense mutations or in-frame deletions or insertions, often outside the functionally critical UCH domain in this tumor suppressor protein. Thus, precisely how these mutations inactivate BAP1 is unknown. Here, we show how these mutations affect BAP1 interactions with the Polycomb group-like protein, ASXL2, using combinations of computational modeling technology, molecular biology, and in vitro reconstitution biochemistry. We found that the BAP1\u2013ASXL2 interaction is direct and high affinity, occurring through the ASXH domain of ASXL2, an obligate partner for BAP1 enzymatic activity. The ASXH domain was the minimal domain for binding the BAP1 ULD domain, and mutations on the surfaces of predicted helices of ASXH abolished BAP1 association and stimulation of BAP1 enzymatic activity. The BAP1-UCH, BAP1-ULD, and ASXH domains formed a cooperative stable ternary complex required for deubiquitination. We defined four classes of alterations in BAP1 outside the UCH domain, each failing to productively recruit ASXH to the wild-type BAP1 catalytic site via the ULD, resulting in loss of BAP1 ubiquitin hydrolase activity. Our results indicate that many BAP1 mutations act allosterically to inhibit ASXH binding, thereby leading to loss of enzyme activity. Small-molecule approaches to reactivate latent wild-type UCH activity of these mutants might be therapeutically viable.<\/jats:p>\n                  <jats:p>Significance: Combined computational and biochemical approaches demonstrate that the BAP1\u2013ASXL2 interaction is direct and high affinity and that many BAP1 mutations act allosterically to inhibit BAP1\u2013ASXL2 binding. Cancer Res; 78(5); 1200\u201313. \u00a92017 AACR.<\/jats:p>","DOI":"10.1158\/0008-5472.can-17-2876","type":"journal-article","created":{"date-parts":[[2017,12,28]],"date-time":"2017-12-28T09:25:21Z","timestamp":1514453121000},"page":"1200-1213","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Familial and Somatic\n                    <i>BAP1<\/i>\n                    Mutations Inactivate ASXL1\/2-Mediated Allosteric Regulation of BAP1 Deubiquitinase by Targeting Multiple Independent Domains"],"prefix":"10.1158","volume":"78","author":[{"given":"Hongzhuang","family":"Peng","sequence":"first","affiliation":[{"name":"1Wistar Institute, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Prokop","sequence":"additional","affiliation":[{"name":"2HudsonAlpha Genome Sequencing Center, Huntsville, Alabama."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayashree","family":"Karar","sequence":"additional","affiliation":[{"name":"1Wistar Institute, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyewon","family":"Park","sequence":"additional","affiliation":[{"name":"1Wistar Institute, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Cao","sequence":"additional","affiliation":[{"name":"3Washington University in St Louis, St. Louis, Missouri."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. William","family":"Harbour","sequence":"additional","affiliation":[{"name":"4University of Miami School of Medicine, Miami, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Bowcock","sequence":"additional","affiliation":[{"name":"5Icahn School of Medicine at Mount Sinai, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Bruce","family":"Malkowicz","sequence":"additional","affiliation":[{"name":"6University of Pennsylvania and Veterans Affairs Medical Center Philadelphia, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Cheung","sequence":"additional","affiliation":[{"name":"7Fox Chase Cancer Center, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph R.","family":"Testa","sequence":"additional","affiliation":[{"name":"7Fox Chase Cancer Center, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Frank J.","family":"Rauscher","sequence":"additional","affiliation":[{"name":"1Wistar Institute, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2018,2,28]]},"reference":[{"key":"2022061700423310000_bib1","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/sj.onc.1201861","article-title":"BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression","volume":"16","author":"Jensen","year":"1998","journal-title":"Oncogene"},{"key":"2022061700423310000_bib2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1158\/0008-5472.CAN-08-3355","article-title":"BRCA1-associated protein 1 interferes with BRCA1\/BARD1 RING heterodimer activity","volume":"69","author":"Nishikawa","year":"2009","journal-title":"Cancer Res"},{"key":"2022061700423310000_bib3","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1128\/MCB.01517-08","article-title":"Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle regulator host cell factor 1","volume":"29","author":"Misaghi","year":"2009","journal-title":"Mol Cell Biol"},{"key":"2022061700423310000_bib4","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1534\/genetics.107.075739","article-title":"A genetic screen identifies novel polycomb group genes in Drosophila","volume":"176","author":"Gayt\u00e1n de Ayala Alonso","year":"2007","journal-title":"Genetics"},{"key":"2022061700423310000_bib5","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nature08966","article-title":"Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB","volume":"465","author":"Scheuermann","year":"2010","journal-title":"Nature"},{"key":"2022061700423310000_bib6","first-page":"F21","article-title":"Ubiquitin in signal transduction and cell transformation","volume":"1288","author":"Isaksson","year":"1996","journal-title":"Biochim Biophys Acta"},{"key":"2022061700423310000_bib7","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.sbi.2014.02.002","article-title":"Paradigms of protein degradation by the proteasome","volume":"24","author":"Inobe","year":"2014","journal-title":"Curr Opin Struct Biol"},{"key":"2022061700423310000_bib8","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1126\/science.1194472","article-title":"Frequent mutation of BAP1 in metastasizing uveal melanomas","volume":"330","author":"Harbour","year":"2010","journal-title":"Science"},{"key":"2022061700423310000_bib9","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat Genet"},{"key":"2022061700423310000_bib10","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat Genet"},{"key":"2022061700423310000_bib11","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/ng.910","article-title":"Germline mutations in BAP1 predispose to melanocytic tumors","volume":"43","author":"Wiesner","year":"2011","journal-title":"Nat Genet"},{"key":"2022061700423310000_bib12","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1136\/jmedgenet-2011-100156","article-title":"Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers","volume":"48","author":"Abdel-Rahman","year":"2011","journal-title":"J Med Genet"},{"key":"2022061700423310000_bib13","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc3459","article-title":"BAP1 and cancer","volume":"13","author":"Carbone","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"2022061700423310000_bib14","article-title":"BAP1 tumor predisposition syndrome","author":"Pilarski","year":"1993"},{"key":"2022061700423310000_bib15","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1126\/science.1221711","article-title":"Loss of the tumor suppressor BAP1 causes myeloid transformation","volume":"337","author":"Dey","year":"2012","journal-title":"Science"},{"key":"2022061700423310000_bib16","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1158\/0008-5472.CAN-15-3371","article-title":"Bap1 is a bona fide tumor suppressor: genetic evidence from mouse models carrying heterozygous germline Bap1 mutations","volume":"76","author":"Kadariya","year":"2016","journal-title":"Cancer Res"},{"key":"2022061700423310000_bib17","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/ng.868","article-title":"De novo nonsense mutations in ASXL1 cause Bohring-Opitz syndrome","volume":"43","author":"Hoischen","year":"2011","journal-title":"Nat Genet"},{"key":"2022061700423310000_bib18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/gm415","article-title":"De novo truncating mutations in ASXL3 are associated with a novel clinical phenotype with similarities to Bohring-Opitz syndrome","volume":"5","author":"Bainbridge","year":"2013","journal-title":"Genome Med"},{"key":"2022061700423310000_bib19","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ccr.2012.06.032","article-title":"ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression","volume":"22","author":"Abdel-Wahab","year":"2012","journal-title":"Cancer Cell"},{"key":"2022061700423310000_bib20","first-page":"1","article-title":"ASXL1 mutations in myeloid neoplasms: pathogenetic considerations, impact on clinical outcomes and survival","volume":"2017","author":"Alvarez Argote","journal-title":"Curr Med Res Opin"},{"key":"2022061700423310000_bib21","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jmb.2007.03.047","article-title":"The structurally disordered KRAB repression domain is incorporated into a protease resistant core upon binding to KAP-1-RBCC domain","volume":"370","author":"Peng","year":"2007","journal-title":"J Mol Biol"},{"key":"2022061700423310000_bib22","doi-asserted-by":"crossref","first-page":"18000","DOI":"10.1074\/jbc.M001499200","article-title":"Biochemical analysis of the Kruppel-associated box (KRAB) transcriptional repression domain","volume":"275","author":"Peng","year":"2000","journal-title":"J Biol Chem"},{"key":"2022061700423310000_bib23","doi-asserted-by":"crossref","first-page":"35670","DOI":"10.1074\/jbc.M109.032086","article-title":"Epigenetic gene silencing by the SRY protein is mediated by a KRAB-O protein that recruits the KAP1 co-repressor machinery","volume":"284","author":"Peng","year":"2009","journal-title":"J Biol Chem"},{"key":"2022061700423310000_bib24","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1002\/jcc.10349","article-title":"A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations","volume":"24","author":"Duan","year":"2003","journal-title":"J Comput Chem"},{"key":"2022061700423310000_bib25","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/prot.20251","article-title":"Making optimal use of empirical energy functions: force-field parameterization in crystal space","volume":"57","author":"Krieger","year":"2004","journal-title":"Proteins"},{"key":"2022061700423310000_bib26","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/prot.20921","article-title":"MUSTANG: a multiple structural alignment algorithm","volume":"64","author":"Konagurthu","year":"2006","journal-title":"Proteins"},{"key":"2022061700423310000_bib27","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1093\/bioinformatics\/btm404","article-title":"Clustal W and Clustal X version 2.0","volume":"23","author":"Larkin","year":"2007","journal-title":"Bioinformatics"},{"key":"2022061700423310000_bib28","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1002\/prot.24065","article-title":"Ab initio protein structure assembly using continuous structure fragments and optimized knowledge-based force field","volume":"80","author":"Xu","year":"2012","journal-title":"Proteins"},{"key":"2022061700423310000_bib29","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J Comput Chem"},{"key":"2022061700423310000_bib30","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1158\/0008-5472.CAN-15-0295","article-title":"Germline BAP1 mutational landscape of asbestos-exposed malignant mesothelioma patients with family history of cancer","volume":"76","author":"Ohar","year":"2016","journal-title":"Cancer Res"},{"key":"2022061700423310000_bib31","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/prot.23147","article-title":"Structural characterization of human Uch37","volume":"80","author":"Burgie","year":"2012","journal-title":"Proteins"},{"key":"2022061700423310000_bib32","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4161\/cc.11.1.18475","article-title":"The HARE-HTH and associated domains: novel modules in the coordination of epigenetic DNA and protein modifications","volume":"11","author":"Aravind","year":"2012","journal-title":"Cell Cycle"},{"key":"2022061700423310000_bib33","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/nature08448","article-title":"JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin","volume":"461","author":"Dawson","year":"2009","journal-title":"Nature"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/78\/5\/1200\/2602654\/1200.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/78\/5\/1200\/2602654\/1200.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T02:39:35Z","timestamp":1655433575000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/78\/5\/1200\/543284\/Familial-and-Somatic-BAP1-Mutations-Inactivate"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,28]]},"references-count":33,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,2,28]]},"published-print":{"date-parts":[[2018,3,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-17-2876","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22418772.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22418778","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22418778.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22418775","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22418772","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22418775.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22418769.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22418769","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6510222.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6510222","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,28]]}}}